Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

EvidenceVariable: Treatment-induced changes in phospho-protein signaling (NCT05327010)

Official URL: https://fevir.net/resources/EvidenceVariable/583776 Version: 1.0.0-ballot3
Standards status: Informative Computable Name: Treatment_induced_changes_in_phospho_protein_signaling_NCT05327010
Other Identifiers: FEvIR Object Identifier: FEvIR Object Identifier#583776, FEvIR Linking Identifier: NCT05327010-otherOutcome-0, OID:2.16.840.1.113883.4.642.40.44.24.182

Copyright/Legal: Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

Reverse phase proteomic array in pre- and on-treatment tumor biopsy samples conducted to assess treatment-induced changes in phospho-protein signaling, to correlate with treatment response and progression, and to assess changes in the levels of cytotoxic T lymphocyte precursor.

version: 2; Last updated: 2026-07-27 13:49:52+0000

Profile: VariableDefinition

ArtifactPublicationStatus: Active

url: EvidenceVariable Treatment-induced changes in phospho-protein signaling (NCT05327010)

identifier: FEvIR Object Identifier/583776, FEvIR Linking Identifier/NCT05327010-otherOutcome-0, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.24.182

version: 1.0.0-ballot3

name: Treatment_induced_changes_in_phospho_protein_signaling_NCT05327010

title: Treatment-induced changes in phospho-protein signaling (NCT05327010)

citeAs:

Treatment-induced changes in phospho-protein signaling (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583776. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583776. Computable resource at: https://fevir.net/resources/EvidenceVariable/583776#json.

status: Active

date: 2026-11-05 14:34:28+0000

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

Reverse phase proteomic array in pre- and on-treatment tumor biopsy samples conducted to assess treatment-induced changes in phospho-protein signaling, to correlate with treatment response and progression, and to assess changes in the levels of cytotoxic T lymphocyte precursor.

copyright:

Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

Definitions

-Concept
*Treatment-induced changes in phospho-protein signaling Reverse phase proteomic array in pre- and on-treatment tumor biopsy samples conducted to assess treatment-induced changes in phospho-protein signaling, to correlate with treatment response and progression, and to assess changes in the levels of cytotoxic T lymphocyte precursor.

handling: Evidence variable handling not specified

Timings

-Text
*Up to 2 years